Founded
2016
CEO
Iraj Ali
Founders
Karl Peggs
Charles Swanton
Mark Lowdell
Sergio Quezada
% Shareholding
34%
Stage
Clinical
Number of employees
150+
Listed
NASDAQ
(March 2021)
Clinical programmes
2

Unless stated all data at 31 December 2020

Achilles website

Achilles Therapeutics is a clinical-stage biopharmaceutical company developing novel cancer immunotherapies targeting clonal neoantigens: protein markers unique to each individual that are expressed on the surface of every cancer cell.

Achilles uses DNA sequencing data from each patient, together with a proprietary bioinformatics platform, to identify clonal neoantigens specific to that patient and enable the development of personalised cell therapies. Targeting multiple clonal neoantigens that are present on all cancer cells, but not on healthy cells, allows individualised treatments to target and destroy tumours without harming healthy tissues.

Achilles has built a world-leading bioinformatics platform to identify clonal neoantigens from each patient’s unique tumour profile. Their proprietary PELEUSTM platform was developed from their co-founder Professor Charles Swanton’s academic TRACERx bioinformatics pipeline and has been validated using Achilles’ exclusive access to the TRACERx sequence data.

Investment opportunity

  • TILs have shown convincing efficacy in solid tumours*
  • Leveraging clonal neoantigens to develop specific immunotherapies to increase response rates and reduce risk of relapse

Unmet medical need

  • Lung cancer has limited treatment options and is the leading cause of cancer deaths

Market opportunity:

  • 234,000 patient opportunity in non-small cell lung cancer**
  • In 2021, over 207,000 patients are expected to be diagnosed with melanoma in the US***

Key risks:

  • Highly innovative concept in emerging space
  • Complex manufacturing
  • Increasing competition

 

* Source: Rosenberg et al 2011 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3131487/pdf/nihms286994.pdf 

** Source: https://pubmed.ncbi.nlm.nih.gov/33600992/ 

*** Source - https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/annual-cancer-facts-and-figures/2021/cancer-facts-and-figures-2021.pdf 

The Achilles Therapeutics pipeline

Research Pre-clinical Clinical
  • Non-small cell lung cancer

  • Melanoma (monotherapy)

Syncona team

Martin Murphy

Martin Murphy

Martin is Chief Executive Officer of Syncona Investment Management Ltd. He co-founded Syncona in 2012 alongside The Wellcome Trust. Since then, Martin has been closely involved in the foundation and development of seven Syncona companies, including: Achilles Therapeutics, Autolus, OMass Therapeutics, Quell Therapeutics, Anaveon and Resolution Therapeutics. He is Chairman of Autolus, Quell and Anav…
View Martin's biography
Qualification
PhD
Alex Hamilton

Alex Hamilton

Alex is a Partner of Syncona Investment Management Ltd. He is a Director on the Board of SwanBio Therapeutics. Previously, he was a member of the Healthcare Investment Banking team at Jefferies, where he worked on a range of financings and mergers and acquisitions across the biotechnology, pharmaceutical and healthcare sectors. Alex has a PhD in Immunology from the University of Cambridge.
View Alex's biography
Qualification
PhD
Elisa Petris

Elisa Petris

Elisa is a Partner of Syncona Investment Management Ltd. She is a Director on the Board of Quell Therapeutics and Neogene Therapeutics and was previously on the Board of former portfolio company Blue Earth Diagnostics. She was closely involved in the foundation of both Quell and Blue Earth, including their operational and strategic set-up. Previously, she was a Senior Associate at Michel Dyens &am…
View Elisa's biography
Qualification
PhD

Achilles Therapeutics leaders and founders

Achilles Therapeutics publications & presentations

Show presentations from

Achilles Corporate Presentation - May 2021

Download PDF (4.28Mb)

Achilles - Jefferies Healthcare Conference Presentation

Download PDF (2.72Mb)

Other cell therapy portfolio companies